Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 342837-2350	SERIAL NO. 10/685,353
		APPLICANT Ryan C. HOLCOMB et al.	
		FILING DATE October 9, 2003	GROUP ART UNIT 1614

OIPE 2116 JUN 0 4 2004 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
D.K.	A1	3,654,275	April 4, 1972	McManus ~~Quinoxalinecarboxamide Antiinflammatory Agents~~			10-15-69

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
D.K.	A2	43 41 663 A1	6-8-95	DE				
	A3	02/099388 A2	12-12-02	WO				
	A4	03/007958 A1	1-30-03	WO				
	A5	03/093245 A1	11-13-03	WO				
	A6	2004/033436 A1	4-22-03	WO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

D.K.	A7	Menke, et al., "Expression Cloning of a Human B_1 Bradykinin Receptor", J. Biol. Chem., 269(34):21583-21586 (1994).
	A8	Hess, et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor", Biochem Biophys. Res. Commun., 184:260-268 (1992)
	A9	Burch, et al., "Bradykinin Receptor Antagonists", Med., 30:237-269 (1990).
	A10	Ammons, et al., "Effects of Intracardiac Bradykinin on T_2-T_5 Medial Spinothalamic Cells", The American Physiological Society, 0363-6119, R147-R152 (1985).
	A11	Costello, et al., "Suppression of Carageenan-Induced Hyperalgesia, Hyperthermia and Edema by a Bradykinin Antagonist", European Journal of Pharmacology, 171:259-263 (1989).
	A12	Laneuville, et al., "Bradykinin Analogue Blocks Bradykinin-induced Inhibition of a Spinal Nociceptive Reflex in the Rat", European Journal of Pharmacology, 137:281-285 (1987).
	A13	Steranka, et al., "Antinociceptive Effects of Bradykinin Antagonists", European Journal of Pharmacology, 136:261-262 (1987).
	A14	Steranka, et al., "Bradykinin as a Pain Mediator: Receptors are Localized to Sensory Neurons, and Antagonists have Analgesic Actions", Neurobiology, 85:3245-3249 (1988).
	A15	Whalley, et al., "The Effect of Kinin Agonists and Antagonists on the Pain Response of the Human Blister Base", Naunyn Schmiederberg's Arch. Pharmacol., 336:652-655 (1987).
	A16	Back, et al., "Determination of Components of the Kallikrein-Kinin System in the Cerebrospinal Fluid of Patients with Various Diseases", Res. Clin. Stud. Headaches, 3:219-226 (1972).
	A17	Ness, et al., "Visceral Pain: a Review of Experimental Studies", Pain, 41:167-234 (1990).
	A18	Aasen, et al., "Plasma kallikrein Activity and Prekallikrein Levels during Endotoxin Shock in Dogs", Eur. Surg. Res., 10:50-62(1978).
	A19	Aasen, et al., "Plasma Kallikrein-Kinin System in Septicemia", Arch. Surg., 118:343-346 (1983).
	A20	Katori, et al., "Evidence for the Involvement of a Plasma Kallikrein-Kinin System in the Immediate Hypotension Produced by Endotoxin in Anaesthetized Rats", Br. J. Pharmacol., 98:1383-1391 (1989).
	A21	Marceau, et al., "Pharmacology of Kinins: Their Relevance to Tissue Injury and Inflammation", Gen. Pharmacol., 14:209-229 (1983).

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 342837-2350	SERIAL NO. 10/685,353
INFORMATION DISCLOSURE CITATION		APPLICANT Ryan C. HOLCOMB et al.	
(Use several sheets if necessary)		FILING DATE October 9, 2003	GROUP ART UNIT 1614

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

D.C.	A22	Weipert, et al., "Attenuation of arterial blood pressure fall endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp^2, Thi^{5,8}, DPhe^7]-BK (B4148)", Brit J. Pharm., 94:282-284 (1988).
	A23	Haberland, "The Role of Kininogenases, Kinin Formation and Kininogenase Inhibition in Post Traumatic Shock and Related Conditions", Klinische Woochen-Schrift, 56:325-331 (1978).
	A24	Ellis, et al., "Inhibition of Bradykinin-and Kallikrein-Induced Cerebral Arteriolar Dilation by Specific Bradykinin Antagonist", Stroke, 18:792-795 (1987).
	A25	Kamitani, et al., "Evidence for a Possible Role of the Brain Kallikrein-Kinin System in the Modulation of the Cerebral Circulation", Circ. Res., 57:545-552 (1985).
	A26	Barnes, "Inflammatory Mediator Receptors and Asthma", Am. Rev. Respir. Dis., 135:S26-S31 (1987).
	A27	Burch, et al., "Bradykinin Receptor Antagonists", Med Res. Reviews., 10::237-269 (1990).
	A28	Fuller, et al., "Bradykinin-induced Bronchoconstriction in Humans", Am. Rev. Respir. Dis., 135:176-180 (1987).
	A29	Jin, et al., "Inhibition of Bradykinin-Induced Bronchoconstriction in the Guinea-Pig by a Synthetic B_2 Receptor Antagonist", Br. J. Pharmacol., 97:598-602 (1989).
	A30	Polosa, et al., "Contribution of Histamine and Prostanoids to Bronchoconstriction Provoked by Inhaled Bradykinin in Atopic Asthma", Allergy, 45:174-182 (1990).
	A31	Baumgarten, et al., "Concentrations of Glandular Kallikrein in Human Nasal Secretions Increase During Experimentally Induced Allergic Rhinitis", J. Immunology, 137:1323-1328 (1986).
	A32	Proud, et al., "Nasal Provocation with Bradykinin Induces Symptoms of Rhinitis and a Sore Throat", Am. Rev. Respir Dis., 137:613-616 (1988).
	A33	Seabrook, et al., "Expression of B_1 and B_2 Bradykinin Receptor mRNA and Their Functional Roles in Sympathetic Ganglia and Sensory Dorsal Root Ganglia Neurons from Wild-type and B_2 Receptor Knockout Mice", Neuropharmacology, 36(7):1009-17 (1997).
	A34	Elguero, et al., Nonconventional Analgesics: Bradykinin Antagonists, An. Real. Acad. Farm., 63:173-190 (1997).
	A35	Artis, et al., "Structured-based design of Six novel classes of nonpeptide antagonists of the bradykinin B_2 receptor", Bioganic & Med. Chem. Letters, 10:2421-2425, (2000)
	A36	Dziadulewicz, et al., "The design of non-peptide human bradykinin B_2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold", Bioganic & Med. Chem. Letters, 9:463-468, (1999)

EXAMINER		**DATE CONSIDERED**	6/9/05
*	**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**		